Showing results (1-10 of 85) with videos related to
Sort By:
Pageof 9
The Open Neurology Journal|June 23, 2016
Cutaneous and Mixed Nerve Silent Period Recordings in Symptomatic Paroxysmal Kinesigenic DyskinesiaJulien Cogez, Olivier Etard, Nathalie Derache, et al.Journal of Neurology|April 9, 2009
Quantification and clinical relevance of brain atrophy in multiple sclerosis: a reviewBlandine Grassiot, Béatrice Desgranges, Francis Eustache, et al.Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism|September 1, 2011
Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidenceDenis Vivien, Maxime Gauberti, Axel Montagne, et al.BMC Neurology|July 12, 2011
Stroke in hereditary hemorrhagic telangiectasia patients. New evidence for repeated screening and early treatment of pulmonary vascular malformations: two case reportsEspartaco Ribeiro, Julien Cogez, Emmanuel Babin, et al.Plos One|March 17, 2016
The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-AnalysisPierre Branger, Jean-Jacques Parienti, Maria Pia Sormani, et al.Plos One|February 2, 2018
Socio-economic status influences access to second-line disease modifying treatment in Relapsing Remitting Multiple Sclerosis patientsFloriane Calocer, Olivier Dejardin, Karine Droulon, et al.Trials|October 31, 2019
Neuropsychological management of multiple sclerosis: evaluation of a supervised and customized cognitive rehabilitation program for self-used at home (SEPIA): protocol for a randomized controlled trialCaroline Harand, France Daniel, Audrey Mondou, et al.BMC Neurology|August 22, 2012
Inflammatory-like presentation of CADASIL: a diagnostic challengeNicolas Collongues, Nathalie Derache, Frédéric Blanc, et al.Frontiers in Immunology|October 19, 2020
Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune MonitoringKathy Khoy, Delphine Mariotte, Gilles Defer, et al.Stroke|August 6, 2011
Preclinical evidence toward the use of ketamine for recombinant tissue-type plasminogen activator-mediated thrombolysis under anesthesia or sedationClement Gakuba, Maxime Gauberti, Mikael Mazighi, et al.Pageof 9